临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 74050-98-9

Ketanserin

中文名称: 凯他色林
CAS号:74050-98-9
分子式: C22H22FN3O3 分子量: 395.43
产品形式: Free Base
研发状态: Recruiting
研发用途: Basic Science
研究机构: Gitte Moos Knudsen; Rigshospitalet Denmark
研发日期: March 3 2017
研发阶段: Phase 1
Ketanserin (R41468, Ketanserinum) is a specific 5-HT2A serotonin receptor antagonist with Ki of 2.5 nM for rat and human 5-HT2A, used as an antihypertensive drug.

CAS: 73963-72-1

Cilostazol (OPC-13013)

中文名称:西洛他唑
CAS号:73963-72-1
分子式: C20H27N5O2 分子量: 369.46
产品形式: free base
研发状态: Completed
研发用途: Migraine
研究机构: Danish Headache Center
研发日期: May 23 2017
研发阶段: Not Applicable
Cilostazol (Pletal,OPC-13013) is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.

CAS: 738-70-5

Trimethoprim

中文名称: 甲氧苄氨嘧啶
CAS号:738-70-5
分子式: C14H18N4O3 分子量: 290.32
产品形式: free base
研发状态: Completed
研发用途: Clinical Audit; Quality Improvement
研究机构: University of British Columbia; Ministry of Health British Columbia
研发日期: September 23 2021
研发阶段: Not Applicable
Trimethoprim (BW 56-72, NIH 204, NSC-106568) is a bacteriostatic antibiotic mainly used in the prophylaxis and treatment of urinary tract infections.

CAS: 738606-46-7

ETC-1002

中文名称:贝派地酸
CAS号:738606-46-7
分子式: C19H36O5 分子量: 344.49
产品形式: free base
研发状态: Recruiting
研发用途: Hypercholesterolemia
研究机构: Esperion Therapeutics Inc.
研发日期: January 12 2023
研发阶段: Phase 2
ETC-1002 (Bempedoic acid, ESP-55016),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).

CAS: 737789-87-6

Relugolix

中文名称:瑞卢戈利
CAS号:737789-87-6
分子式: C29H27F2N7O5S 分子量: 623.63
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Androgen Deprivation Therapy; Locally Advanced Prostate Cancer
研究机构: University of Oklahoma
研发日期: Aug-24
研发阶段: Phase 1
Relugolix (RVT-601, TAK-385) is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) with IC50 of 0.33 nM and 0.32 nM for human GnRHR and monkey GnRHR, respectively.

CAS: 736992-21-5

Elamipretide (MTP-131)

中文名称:D-精氨酰-2,6-二甲基-L-酪氨酰-L-赖氨酰-L-苯丙氨酰胺
CAS号:736992-21-5
分子式: C32H49N9O5 分子量: 639.79
产品形式: Free Base
研发状态: Recruiting
研发用途: Diaphragm Injury; Mechanical Ventilation Complication
研究机构: University Hospital Montpellier
研发日期: February 18 2022
研发阶段: Not Applicable
Elamipretide (MTP-131, SS-31, D-Arg-Dmt-Lys-Phe-NH2) is a cytochrome c peroxidase inhibitor. Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.